Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 1 | -$0.71 | -$0.71 | -$0.71 |
Q2 2025 | 1 | -$0.52 | -$0.52 | -$0.52 |
Q3 2025 | 1 | -$0.71 | -$0.71 | -$0.71 |
Q4 2025 | 1 | -$0.76 | -$0.76 | -$0.76 |
Q1 2026 | 1 | -$0.70 | -$0.70 | -$0.70 |
Q2 2026 | 1 | -$0.70 | -$0.70 | -$0.70 |
Q3 2026 | 1 | -$0.65 | -$0.65 | -$0.65 |
Q4 2026 | 1 | -$0.70 | -$0.70 | -$0.70 |
Evaxion Biotech A/S last posted its earnings results on Wednesday, March 26th, 2025. The company reported $-0.8 earnings per share for the quarter, missing analysts' consensus estimates of $-0.26 by $0.54. The company had revenue of 122,000 for the quarter and had revenue of 3.34 M for the year. Evaxion Biotech A/S has generated $-10 earnings per share over the last year ($-10 diluted earnings per share) and currently has a price-to-earnings ratio of -0.05. Evaxion Biotech A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
04/01/2025 | Q4 2024 | N/A | -$0.49 | N/A | $1.66 M | $122,000 |
09/28/2024 | Q3 2024 | N/A | -$0.07 | N/A | $123,333 | $3.03 M |
06/28/2024 | Q2 2024 | N/A | -$0.23 | N/A | $52,000 | $153,887 |
08/14/2024 | Q1 2024 | $0.10 | $0.05 | -0.05 | $37,000 | $50,881 |
03/26/2024 | Q4 2023 | N/A | -$0.33 | N/A | N/A | $73,597 |
09/07/2023 | Q3 2023 | N/A | -$0.41 | N/A | N/A | $0 |
08/17/2023 | Q2 2023 | N/A | -$0.42 | N/A | N/A | $0 |
03/31/2023 | Q1 2023 | N/A | -$0.48 | N/A | N/A | $0 |
04/27/2023 | Q4 2022 | N/A | -$0.57 | N/A | N/A | $0 |
11/13/2022 | Q3 2022 | -$17.00 | -$0.48 | 16.52 | N/A | $0 |
06/30/2022 | Q2 2022 | N/A | -$0.41 | N/A | N/A | $0 |
03/31/2022 | Q1 2022 | N/A | -$0.50 | N/A | N/A | $0 |
03/31/2022 | Q4 2021 | N/A | -$0.77 | N/A | N/A | $0 |
09/30/2021 | Q3 2021 | N/A | -$0.55 | N/A | N/A | $0 |
06/30/2021 | Q2 2021 | N/A | -$0.72 | N/A | N/A | $0 |
03/31/2021 | Q1 2021 | N/A | -$0.46 | N/A | N/A | $0 |
04/07/2021 | Q4 2020 | N/A | -$0.53 | N/A | N/A | $0 |
09/30/2020 | Q3 2020 | N/A | -$0.50 | N/A | N/A | $0 |
06/30/2020 | Q2 2020 | N/A | -$0.38 | N/A | N/A | $0 |
03/31/2020 | Q1 2020 | N/A | -$0.32 | N/A | N/A | $0 |
Evaxion Biotech A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 26th, 2025 based offlast year's report dates.
The conference call for Evaxion Biotech A/S's latest earnings report can be listened to online.
The conference call transcript for Evaxion Biotech A/S's latest earnings report can be read online.
Evaxion Biotech A/S (:EVAX) has a recorded annual revenue of $3.34 M.
Evaxion Biotech A/S (:EVAX) has a recorded net income of $-10,567,000.Evaxion Biotech A/S has generated $-10 earnings per share over the last four quarters.
Evaxion Biotech A/S (:EVAX) has a price-to-earnings ratio of -0.05 and price/earnings-to-growth ratio is 0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED